More from the company
Publicerat: 2018-04-30 10:05:46
RhoVac AB ("RhoVac") announced today that the company will be presenting at Aktiesprarnas Aktiefrukost in Stockholm, Sweden and at 3rd Annual Advances in Immuno Oncology Congress, London, UK. In June, RhoVac will attend the International Convention, Boston, USA.
RhoVac's CEO Anders Ljungqvist will present status and plans for the company's drug candidate RV001 at Aktiespararnas Aktiefrukost, Operatorrassen, Stockholm, Sweden May 3, 2018. Registration for this event is via https://www.aktiespararna.se/aktiviteter/aktiefrukost-stockholm-3-maj. Anders Ljungqvist will attend 3rd Annual Advances in Immuno-Oncology Congress 24-25 May 2018 in London, UK (https://www.immunooncology-congress.com/). Not only research institutes, but also global pharmaceutical companies and biotechnology companies are attending this conference. RhoVac will also attend the Biotechnology Innovation Organization's (BIO) Conference International Convention, Boston, USA, between 4-7 June 2018. At BIO more than 1100 biotechnology companies, academic institutions and other related organizations from USA and over 30 other countries are represented.